MMJ PhytoTech trades on the Australian Stock Exchange under the ticker code MMJ.
Current share price:
Results from the Phase 1 Clinical Trial have been published. The article “Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology” has been published in an international, peer-reviewed medical journal, Clinical Pharmacology in Drug Development. This clinical trial was completed in March 2016, and demonstrated the […]
In a new investment report, Banyan Tree Investment Group discusses key investment drivers for MMJ Phytotech and highlights the unique investment proposition the company offers to investors. Click here to read the full report. Facebook1Twitter0Google plus0Linkedin0X
PhytoTech Therapeutics’ first Phase 2 clinical trial, which commenced in February 2017, is continuing as planned. This clinical trial is an open-label study aimed at evaluating the safety, tolerability and efficacy of oral administration of PTL101 as an adjunctive treatment for children with refractory epilepsy. The PTL101 drug beads are utilising proprietary formulation developed through […]
Read the Haywood Securities investment report Facebook0Twitter0Google plus0Linkedin0X